Tipranavir: A Ritonavir-Boosted Protease Inhibitor

A Viewpoint by Dushyantha T. Jayaweera

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Hicks C. RESIST-1: a phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir to an optimized comparator protease inhibitor/ritonavir regimen (CPI/r) in antiretroviral (ARV) experienced patients: 24-week data [abstract no. 3726 plus presentation]. 44th ICAAC; 2004 Oct 31–Nov 2; Washinton, DC [online]. Available from http://www.medadvocates.org [Accessed 2005 Feb 17]
Cooper D, Hicks C, Cahn P, et al. 24-week RESIST study analyses: the efficacy of tipranavir/ritonavir (TPV/r) is superior to lopinavir/ritonavir (LPV/r), and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR) [abstract no. 560 plus poster]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston [online]. Available from URL: http://www.retroconference.org [Accessed 2005 Mar 4]

Division of Infectious Diseases, Department of Medicine, University of Miami, Miami, Florida, USA
Dushyantha T. Jayaweera

Authors

Dushyantha T. Jayaweera
View author publications
You can also search for this author in PubMed Google Scholar

Jayaweera, D.T. Tipranavir: A Ritonavir-Boosted Protease Inhibitor. Drugs 65, 1678–1679 (2005). https://doi.org/10.2165/00003495-200565120-00007

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.